Enoxaparin Ledraxen®

Biosimilar medicine authorized by the AEMPS

Enoxaparin Ledraxen®

ACTIVE PRINCIPLE:
Enoxaparin Sodium

INDICATION:
venous thrombosis

DATE:
08/08/2019

STATUS:
Authorized

MORE INFORMATION

BioSim Newsletter

Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.

SUBSCRIBE